

General information about company	
Scrip code*	506128
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE383L01019
Name of company	Parnax Lab Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	14-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	03-11-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Second quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited
Segment Reporting	Single segment
Description of single segment	PHARMACEUTICALS
Start date and time of board meeting	14-11-2025 16:00
End date and time of board meeting	14-11-2025 17:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	15-02-2023
Indicate Company website link for updated RPT policy of the Company	<a href="https://naxparlab.com/wp-content/uploads/2023/04/Policy-on-Related-Party-Transactions.pdf">https://naxparlab.com/wp-content/uploads/2023/04/Policy-on-Related-Party-Transactions.pdf</a>
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No The disclosure for the default on Loans and Debt Securities is not applicable to the entity.

Financial Results – Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-07-2025	01-04-2025	
Date of end of reporting period		30-09-2025	30-09-2025	
Whether results are audited or unaudited		Unaudited	Unaudited	
Nature of report standalone or consolidated		Standalone	Standalone	
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>			
<b>1</b>	<b>Income</b>			
	Revenue from operations	170.11	366.86	
	Other income	19.67	38.36	
	<b>Total income</b>	<b>189.78</b>	<b>405.22</b>	
<b>2</b>	<b>Expenses</b>			
(a)	Cost of materials consumed	46.36	63.41	
(b)	Purchases of stock-in-trade	23.77	119.77	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-10.18	12.27	
(d)	Employee benefit expense	22.51	43.33	
(e)	Finance costs	1.54	2.52	
(f)	Depreciation, depletion and amortisation expense	1.67	3.25	
(g)	<b>Other Expenses</b>			
1	Other Expenses	37.96	63.13	
	<b>Total other expenses</b>	<b>37.96</b>	<b>63.13</b>	
	<b>Total expenses</b>	<b>123.63</b>	<b>307.68</b>	
<b>3</b>	<b>Total profit before exceptional items and tax</b>	<b>66.15</b>	<b>97.54</b>	
4	Exceptional items	0	0	
<b>5</b>	<b>Total profit before tax</b>	<b>66.15</b>	<b>97.54</b>	
<b>6</b>	<b>Tax expense</b>			
7	Current tax	0	0	
8	Deferred tax	16.81	24.71	
<b>9</b>	<b>Total tax expenses</b>	<b>16.81</b>	<b>24.71</b>	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
<b>11</b>	<b>Net Profit Loss for the period from continuing operations</b>	<b>49.34</b>	<b>72.83</b>	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
<b>14</b>	<b>Net profit (loss) from discontinued operation after tax</b>	<b>0</b>	<b>0</b>	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
<b>16</b>	<b>Total profit (loss) for period</b>	<b>49.34</b>	<b>72.83</b>	
17	<a href="#">Other comprehensive income net of taxes</a>	0	0	
<b>18</b>	<b>Total Comprehensive Income for the period</b>	<b>49.34</b>	<b>72.83</b>	
<b>19</b>	<b>Total profit or loss, attributable to</b>			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
<b>20</b>	<b>Total Comprehensive income for the period attributable to</b>			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
<b>21</b>	<b>Details of equity share capital</b>			
	Paid-up equity share capital	1148.56	1148.56	
	Face value of equity share capital	10	10	

22	Reserves excluding revaluation reserve			
<b>23</b>	<b>Earnings per share</b>			
<b>i</b>	<b>Earnings per equity share for continuing operations</b>			
	Basic earnings (loss) per share from continuing operations	0.43	0.63	
	Diluted earnings (loss) per share from continuing operations	0.43	0.63	
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
<b>iii</b>	<b>Earnings per equity share (for continuing and discontinued operations)</b>			
	Basic earnings (loss) per share from continuing and discontinued operations	0.43	0.63	
	Diluted earnings (loss) per share from continuing and discontinued operations	0.43	0.63	
24	Debt equity ratio	0	0	Textual Information( 1)
25	Debt service coverage ratio	0	0	Textual Information( 2)
26	Interest service coverage ratio	0	0	Textual Information( 3)
<b>27</b>	<b>Disclosure of notes on financial results</b>	<b>Textual Information(4)</b>		

Statement of Asset and Liabilities		
Particulars		Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	30-09-2025
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	<b>Assets</b>	
<b>1</b>	<b>Non-current assets</b>	
	Property, plant and equipment	42.36
	Capital work-in-progress	0
	Investment property	0
	Goodwill	0
	Other intangible assets	0
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	<b>Non-current financial assets</b>	
	Non-current investments	1003.08
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	0.25
	<b>Total non-current financial assets</b>	<b>1003.33</b>
	Deferred tax assets (net)	0
	Other non-current assets	0
	<b>Total non-current assets</b>	<b>1045.69</b>
<b>2</b>	<b>Current assets</b>	
	Inventories	101.95
	<b>Current financial asset</b>	
	Current investments	0
	Trade receivables, current	40.55
	Cash and cash equivalents	15.92
	Bank balance other than cash and cash equivalents	76.22
	Loans, current	800.32
	Other current financial assets	0
	<b>Total current financial assets</b>	<b>933.01</b>
	Current tax assets (net)	5.4
	Other current assets	98.33
	<b>Total current assets</b>	<b>1138.69</b>
3	Non-current assets classified as held for sale	356.2
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	<b>Total assets</b>	<b>2540.58</b>
	<b>Total current assets</b>	<b>1138.69</b>
3	Non-current assets classified as held for sale	356.2
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	<b>Total assets</b>	<b>2540.58</b>
	<b>Equity and liabilities</b>	
<b>1</b>	<b>Equity</b>	
	<b>Equity attributable to owners of parent</b>	
	Equity share capital	1148.56
	Other equity	1178.54
	<b>Total equity attributable to owners of parent</b>	<b>2327.1</b>
	Non controlling interest	

	<b>Total equity</b>	2327.1
<b>2</b>	<b>Liabilities</b>	
	<b>Non-current liabilities</b>	
	<b>Non-current financial liabilities</b>	
	Borrowings, non-current	0
	<b>Trade Payables, non-current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	<b>Total Trade payable</b>	0
	Other non-current financial liabilities	
	<b>Total non-current financial liabilities</b>	0
	Provisions, non-current	2.72
	Deferred tax liabilities (net)	65.37
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	<b>Total non-current liabilities</b>	68.09
	<b>Current liabilities</b>	
	<b>Current financial liabilities</b>	
	Borrowings, current	0
	<b>Trade Payables, current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	36.86
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	40.01
	<b>Total Trade payable</b>	76.87
	Other current financial liabilities	45.53
	<b>Total current financial liabilities</b>	122.4
	Other current liabilities	22.72
	Provisions, current	0.27
	Current tax liabilities (Net)	0
	Deferred government grants, Current	0
	<b>Total current liabilities</b>	145.39
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	<b>Total liabilities</b>	213.48
	<b>Total equity and liabilities</b>	2540.58
	<b>Disclosure of notes on assets and liabilities</b>	<b>Textual Information(1)</b>

Other Comprehensive Income			
	Date of start of reporting period	01-07-2025	01-04-2025
	Date of end of reporting period	30-09-2025	30-09-2025
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	0.00	0.00

Cash flow statement, indirect		
Particulars		Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	30-09-2025
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	97.54
2	<b>Adjustments for reconcile profit (loss)</b>	
	Adjustments for finance costs	2.52
	Adjustments for decrease (increase) in inventories	-23.65
	Adjustments for decrease (increase) in trade receivables, current	43.96
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-125.1
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-57.69
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	29.23
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	3.25
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	25.47
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	<b>Total adjustments for reconcile profit (loss)</b>	<b>-152.95</b>
	<b>Net cash flows from (used in) operations</b>	<b>-55.41</b>
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	0.19
	Other inflows (outflows) of cash	0
	<b>Net cash flows from (used in) operating activities</b>	<b>-55.6</b>
3	<b>Cash flows from used in investing activities</b>	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0

	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	3.1
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	-1.33
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	25.47
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	<b>Net cash flows from (used in) investing activities</b>	<b>23.7</b>
<b>4</b>	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	0
	Payments of lease liabilities	0
	Dividends paid	0
	Interest paid	2.52
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	<b>Net cash flows from (used in) financing activities</b>	<b>-2.52</b>
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	<b>-34.42</b>
<b>5</b>	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0
	<b>Net increase (decrease) in cash and cash equivalents</b>	<b>-34.42</b>
	Cash and cash equivalents cash flow statement at beginning of period	50.34
	<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>15.92</b>

**Format for Disclosure of Related Party Transactions (applicable only for half-ye**

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case of party of the Open balance
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								
1	Parnax Lab Limited	AAACK1457E	Naxpar Pharma Private Limited	AADCP2044D	Subsidiary Company	Purchase of goods or services		500	No Remark			109.62	0.1
2	Parnax Lab Limited	AAACK1457E	Naxpar Pharma Private Limited	AADCP2044D	Subsidiary Company	Loan		1500	No Remark			190	694.
3	Parnax Lab Limited	AAACK1457E	Naxpar Pharma Private Limited	AADCP2044D	Subsidiary Company	Any other transaction	Loan Received Back	0	No Remark			110	0
4	Parnax Lab Limited	AAACK1457E	Naxpar Pharma Private Limited	AADCP2044D	Subsidiary Company	Interest received		30	No Remark			24.15	0
5	Parnax Lab Limited	AAACK1457E	Naxpar Medicamentos LLP	AAKFT9298H	Concern in which KMP and/or Relatives of KMP is Interested	Any other transaction	Rent Received	5	No Remark			0.9	0
6	Naxpar Pharma Private Limited	AADCP2044D	Parnax Lab Limited	AAACK1457E	Holding Company	Sale of goods or services		109.62	No Remark			109.62	105.
7	Naxpar Pharma Private Limited	AADCP2044D	Parnax Lab Limited	AAACK1457E	Holding Company	Any other transaction	Loan Taken	190	No Remark			190	694.
8	Naxpar Pharma Private Limited	AADCP2044D	Parnax Lab Limited	AAACK1457E	Holding Company	Any other transaction	Loan Repaid	0	No Remark			110	0
9	Naxpar Pharma Private Limited	AADCP2044D	Parnax Lab Limited	AAACK1457E	Holding Company	Interest paid		24.15	No Remark			24.15	0
10	Naxpar Pharma Private Limited	AADCP2044D	Naxpar Health Concept Pvt Ltd	AACCN1462A	Concern in which KMP and/or Relatives of KMP is Interested	Sale of goods or services		48	No Remark			48	23.8
11	Naxpar Pharma Private Limited	AADCP2044D	Naxpar Health Concept Pvt Ltd	AACCN1462A	Concern in which KMP and/or Relatives of KMP is Interested	Purchase of goods or services		1.67	No Remark			1.67	0.2
12	Naxpar Pharma Private Limited	AADCP2044D	Mr. Mihir P. Shah	AACPS8973L	Key managerial personnel	Any other transaction	Rent Paid	0.99	No Remark			0.99	0
13	Naxpar Pharma	AADCP2044D	Mr. Mihir P. Shah	AACPS8973L	Key managerial personnel	Remuneration		38.94	No Remark			38.94	4.0

	Private Limited												
14	Naxpar Pharma Private Limited	AADCP2044D	Mr. Mihir P. Shah	AACPS8973L	Key managerial personnel	Any other transaction	Loan Taken	5	No Remark			5	1512
15	Naxpar Pharma Private Limited	AADCP2044D	Mr. Mihir P. Shah	AACPS8973L	Key managerial personnel	Any other transaction	Loan Repaid	0	No Remark			80	0
16	Naxpar Pharma Private Limited	AADCP2044D	Mr. Mihir P. Shah	AACPS8973L	Key managerial personnel	Interest paid		55.88	No Remark			55.88	0
17	Naxpar Pharma Private Limited	AADCP2044D	Mr. Baiju M. Shah	AACPS8974P	Key managerial personnel	Remuneration		30	No Remark			30	4.3
18	Naxpar Pharma Private Limited	AADCP2044D	Mr. Baiju M. Shah	AACPS8974P	Key managerial personnel	Any other transaction	Loan Repaid	0	No Remark			94.25	0
19	Naxpar Pharma Private Limited	AADCP2044D	Mr. Baiju M. Shah	AACPS8974P	Key managerial personnel	Interest paid		37.38	No Remark			37.38	0
20	Naxpar Pharma Private Limited	AADCP2044D	Mrs. Ami M. Shah	ANHPS3760R	Key managerial personnel	Any other transaction	Rent Paid	1.2	No Remark			1.2	0
21	Naxpar Pharma Private Limited	AADCP2044D	Mrs. Niyoshi B. Shah	AIDPC6083G	Key managerial personnel	Any other transaction	Rent Paid	1.2	No Remark			1.2	0
22	Naxpar Pharma Private Limited	AADCP2044D	Mr. Prakash M. Shah	AACPS8975N	Key managerial personnel	Remuneration		30	No Remark			30	9.2
23	Naxpar Pharma Private Limited	AADCP2044D	Mr. Binoy Shah	AVZPS7709Q	Key managerial personnel	Remuneration		38.94	No Remark			38.94	2.9
24	Naxpar Pharma Private Limited	AADCP2044D	Mr. Krishang M. Shah	MCVPS8066D	Key managerial personnel	Remuneration		15	No Remark			15	2.2
Total value of transaction during the reporting period												1346.89	